Optimizing Care for Lower-Risk Myelodysplastic Syndromes: Translating Evidence to Clinical Practice - Episode 12
Panelists discuss how the treatment landscape for lower-risk MDS may evolve with emerging novel agents and combination strategies, including studies on luspatercept vs epoetin alfa, luspatercept combinations, elritercept, roxadustat, and canakinumab, potentially offering new options for patients with suboptimal responses to current therapies.
Video content above is prompted by the following:
Luspatercept vs epoetin alfa NTD LR-MDS: ELEMENT-MDS trial.
Jonasova A, et al. Luspatercept plus erythropoietin in LR-MDS. EHA 2024, abstract P1886.
Komrokji RS, et al. Luspatercept plus ESA combinations in LR-MDS. Blood Adv. 2023.
Díez Campelo M, et al. Phase 2 study, elritercept (KER-050). EHA 2024, abstract S183.
Mittelman M, et al. Phase 3, roxadustat: Matterhorn Study. ASH 2023 abstract.
Sallman DA et al. Phase 1b/2 study evaluating canakinumab for 2L treatment in patients with LR-MDS. ASH 2023, abstract 620.